---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-010777"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T05:56:26.207505+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025

## Summary
- Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.
- Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.
- R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.
- Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.
- VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025.

## SEC filing metadata
- accession: 0001628280-25-010777
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/0001628280-25-010777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/mnlo-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-010777
- JSON: https://secwatch.observer/filing/0001628280-25-010777.json
- Plain text: https://secwatch.observer/filing/0001628280-25-010777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.